Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Smith

Showing results (91-100 of 96) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 96 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2026
Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II TrialThomas Pierre Walter, Julien Mazieres, Josiane Otto, et al.
BMC Public Health|January 20, 2026
Wastewater-based surveillance as a proactive public health tool: insights from SARS-CoV-2 monitoring in Kampala, Uganda (2023-2024)Andrew Nsawotebba, Susan Nabadda, Isaac Ssewanyana, et al.
The Lancet. Oncology|March 28, 2024
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 studyStefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, et al.
The Lancet. Oncology|June 1, 2026
[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trialEric Baudin, Alice Durand, Amandine Beron, et al.
The Oncologist|February 12, 2020
Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)Lola-Jade Palmieri, Laurent Mineur, David Tougeron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 28, 2015
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset, Josef Thaler, Richard Greil, et al.
Pageof 10

Showing results (91-100 of 96) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 96 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2026
Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II TrialThomas Pierre Walter, Julien Mazieres, Josiane Otto, et al.
BMC Public Health|January 20, 2026
Wastewater-based surveillance as a proactive public health tool: insights from SARS-CoV-2 monitoring in Kampala, Uganda (2023-2024)Andrew Nsawotebba, Susan Nabadda, Isaac Ssewanyana, et al.
The Lancet. Oncology|March 28, 2024
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 studyStefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, et al.
The Lancet. Oncology|June 1, 2026
[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trialEric Baudin, Alice Durand, Amandine Beron, et al.
The Oncologist|February 12, 2020
Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)Lola-Jade Palmieri, Laurent Mineur, David Tougeron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 28, 2015
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset, Josef Thaler, Richard Greil, et al.
Pageof 10